Skip to Main Content

Amgen’s experimental KRAS-blocking drug is showing a modest improvement in response rates for patients with advanced colon cancer and other solid tumors, according to an update from an early-stage clinical trial released Wednesday evening.

While moving in a positive direction, the new data on the Amgen drug called AMG 510 are unlikely to ease all the doubts that surfaced last year about whether it can be broadly effective against different types of solid tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!